Publications by authors named "M S Wijsenbeek"

There is increasing interest in the use of home-based monitoring in people with chronic lung diseases to improve access to care, support patient self-management, and facilitate the collection of information for clinical care and research. However, integration of home-based monitoring into clinical and research settings requires careful consideration of test performance and other attributes. There is no published guidance from professional respiratory societies to advance the science of home-based monitoring for chronic lung disease.

View Article and Find Full Text PDF

Background: Drugs used to treat rheumatic disease are associated with pneumotoxicity (drug-induced lung disease), but little is known about associated risk factors.

Aim: To determine expert physician-perceived risk factors for developing pneumotoxicity in patients with rheumatologic conditions.

Methods: A modified international 3-tier Delphi exercise was performed.

View Article and Find Full Text PDF

Comprehensive care integrates individual patient needs and is highly valued for patients with pulmonary fibrosis (PF). The importance of a patient-centered care approach is rooted in the unpredictable progressiveness of the disease course in PF. The respiratory impairment associated with PF has a major impact on the quality of life for both patients and their caregivers.

View Article and Find Full Text PDF

Background: In adults with serious respiratory illness, breathlessness is prevalent and associated with reduced health-related quality of life. The aim of this review was to assess the impact of breathing techniques on breathlessness in adults with serious respiratory illness.

Methods: Electronic databases were searched to identify randomised controlled trials testing breathing techniques (techniques that aim to alter the respiratory pattern, excluding respiratory muscle training) in people with serious respiratory illness.

View Article and Find Full Text PDF
Article Synopsis
  • Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are severe lung diseases that require new treatments, prompting a study on the oral drug admilparant (BMS-986278).
  • A phase 2, randomized, double-blind trial was conducted with 278 IPF patients and 125 PPF patients, who received either 30mg or 60mg of admilparant or a placebo twice daily for 26 weeks, all while allowing background treatments.
  • Results showed that the 60mg dose of admilparant significantly slowed the decline in lung function compared to placebo for both IPF and PPF, with a favorable safety profile, supporting further research in phase 3
View Article and Find Full Text PDF